Evaxion files 6-K; EVX-01 phase 2 data slated for ESMO Congress

Rhea-AI Filing Summary

Evaxion A/S furnished a Form 6-K noting it issued a press release about presenting data from its phase 2 trial of the AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025. The press release, dated October 13, 2025, is included as Exhibit 99.1.

The report is also incorporated by reference into Evaxion’s existing U.S. registration statements on Forms S-8, F-3, and F-1. This filing primarily provides disclosure of the upcoming scientific presentation and ensures the press release forms part of the company’s registered offering documents.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number: 001-39950

Evaxion A/S
(Exact Name of Registrant as Specified in Its Charter)

Dr. Neergaards Vej 5f
DK-2970 Hoersholm
Denmark
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ]      Form 40-F [   ]

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Press Release

On October 13, 2025, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits 

Exhibit No.		Description
99.1		Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			Evaxion A/S
			(Registrant)
Date: October 13, 2025		By:	/s/ Birgitte Rønø
			Birgitte Rønø
			Interim Chief Executive Officer

FAQ

What did EVAX announce in this Form 6-K?

Evaxion A/S furnished a press release stating it will present phase 2 data for its AI-designed personalized cancer vaccine EVX-01 at ESMO Congress 2025.

What is the subject of the press release attached to EVAX’s 6-K?

The press release covers Evaxion’s plan to present a breadth of data from a phase 2 trial of EVX-01 at ESMO Congress 2025.

When was the press release issued by EVAX?

The press release was issued on October 13, 2025 and is furnished as Exhibit 99.1.

Which registration statements does this 6-K incorporate into?

It is incorporated by reference into Evaxion’s Forms S-8 (File No. 333-255064), F-3 (File Nos. 333-265132 and 333-285778), and F-1 (File Nos. 333-266050, 333-276505, 333-279153, 333-283304).

What is EVX-01 according to the filing?

EVX-01 is an AI-designed, personalized cancer vaccine developed by Evaxion using its AI-Immunology approach.

Where can I find the detailed announcement within the filing?

See Exhibit 99.1 titled “Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025.”